GO:1902915 negative regulation of protein polyubiquitination: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902915 describes any process that stops, prevents or reduces the frequency, rate or extent of protein polyubiquitination, a central post-translational modification controlling protein stability and signaling.
• Negative regulation is achieved mainly by deubiquitinases (DUBs) that remove ubiquitin chains and by E3 ligase inhibitors or adaptors that block chain assembly.
• Key enzymes include OTUD7B, OTUD5, RNF167, KLHL6, FBXO33, HRD1, TRAF7 and AMFR, which modulate substrates such as SQSTM1/p62, α-synuclein, RLRs, p53, TMEM2, DBP and TSPAN4.
• Dysregulation of this process contributes to cancer metastasis, antiviral immunity, neurodegeneration, ER stress and circadian rhythm disorders.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal dissection of negative regulators in disease-relevant cell types.
• EDITGENE provides end-to-end CRISPR services including KO, point mutation, knock-in, overexpression, library screening and bioinformatics to accelerate research on GO:1902915.
Description
Protein polyubiquitination is a reversible post-translational modification in which multiple ubiquitin molecules are attached to a substrate, often tagging it for proteasomal degradation or altering its interactions. The Gene Ontology term GO:1902915, negative regulation of protein polyubiquitination, captures any process that stops, prevents or reduces the frequency, rate or extent of this modification. This regulatory layer is essential because it sets the threshold for substrate turnover and signaling, and its disruption is linked to immune evasion, cancer progression and neurodegeneration. Understanding GO:1902915 requires identifying the enzymes and adaptors that oppose polyubiquitination, such as deubiquitinases (DUBs) and inhibitory E3 ligase complexes, and mapping their substrates. Recent studies show that DUBs like OTUD7B and OTUD5 directly remove ubiquitin chains from SQSTM1/p62 and α-synuclein, respectively, thereby shaping antiviral responses and neuronal survival. Similarly, E3 ligases such as RNF167, KLHL6, FBXO33, HRD1, TRAF7 and AMFR can be negatively regulated or can themselves mediate atypical ubiquitylation that indirectly reduces polyubiquitination of specific targets. For researchers, GO:1902915 provides a framework to study how cells fine-tune protein stability and signaling, and to develop therapeutic strategies that modulate these checkpoints.
negative regulation of protein polyubiquitination At A Glance
| GO ID | GO:1902915 |
|---|---|
| GO term | negative regulation of protein polyubiquitination |
| Ontology | biological_process |
| Synonym | inhibition of protein polyubiquitination; downregulation of protein polyubiquitinylation; negative regulation of protein polyubiquitylation |
| Major function | Opposes the addition of polyubiquitin chains to substrate proteins, thereby stabilizing substrates or altering their signaling fate. |
| Key enzymes | Deubiquitinases (OTUD7B, OTUD5) and E3 ligases (RNF167, KLHL6, FBXO33, HRD1, TRAF7, AMFR). |
| Substrates | SQSTM1/p62, α-synuclein, RLRs, p53, TMEM2, DBP, TSPAN4. |
| Disease relevance | Cancer metastasis, antiviral immunity, Parkinson's disease, ER stress, circadian disorders. |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, ubiquitination assays, proteomics, imaging. |
What Is GO:1902915?
GO:1902915 is a biological process term defined as any process that stops, prevents or reduces the frequency, rate or extent of protein polyubiquitination. In practice, this includes the action of deubiquitinating enzymes that cleave ubiquitin chains from substrates, the sequestration or inhibition of E1, E2 or E3 enzymes, and the expression of dominant-negative ubiquitin variants that block chain elongation.
Why Is negative regulation of protein polyubiquitination Important in Cell Biology?
Negative regulation of protein polyubiquitination is a critical checkpoint that prevents excessive or inappropriate degradation of key regulatory proteins, thereby maintaining cellular homeostasis and enabling rapid responses to stress or infection. Its dysregulation can lead to accumulation of oncoproteins or loss of tumor suppressors, contributing to cancer and other diseases.
• Controls the stability of immune signaling molecules such as RLRs and SQSTM1/p62, impacting antiviral immunity.
• Modulates neurodegeneration by regulating α-synuclein clearance in Parkinson's disease models.
• Influences cancer progression through p53 polyubiquitination and metastasis in gallbladder cancer.
• Regulates ER stress and apoptosis via TMEM2 ubiquitination in intestinal ischemia/reperfusion.
• Affects circadian rhythm by controlling DBP degradation.
• Participates in viral release by stabilizing TSPAN4 during migrasome formation.
• Provides therapeutic targets for modulating protein degradation pathways.
• Enables precise control of protein half-life in cell engineering and synthetic biology.
• Serves as a paradigm for studying reversible ubiquitination in signal transduction.
• Offers biomarkers for diseases linked to ubiquitin system dysfunction.
What Happens During negative regulation of protein polyubiquitination?
Deubiquitinase-mediated chain removal
In simple terms: Enzymes called deubiquitinases act like scissors that cut ubiquitin chains off target proteins.
Deubiquitinases such as OTUD7B and OTUD5 directly cleave polyubiquitin chains from substrates including SQSTM1/p62 and α-synuclein, preventing their degradation and altering downstream signaling. This activity is a primary mechanism for negative regulation of polyubiquitination.
Inhibition of E3 ligase activity
In simple terms: Some proteins block the enzymes that attach ubiquitin chains, stopping the tagging process.
E3 ligases like RNF167, KLHL6, FBXO33, HRD1, TRAF7 and AMFR can be negatively regulated by adaptors or post-translational modifications, reducing their ability to polyubiquitinate substrates. For example, O-GlcNAcylation of AMFR stabilizes TSPAN4 by limiting its polyubiquitination.
Substrate sequestration or conformational protection
In simple terms: Binding partners can shield a protein so ubiquitin machinery cannot reach it.
Interaction with specific proteins can mask lysine residues on substrates, preventing polyubiquitination. This is observed in the regulation of p53 by FBXO33-driven lactylation, which alters p53 polyubiquitination and promotes gallbladder cancer metastasis.
Atypical ubiquitination and degradation pathways
In simple terms: Some ubiquitin-like modifications do not form classic chains but still lead to degradation.
RNF167 mediates atypical ubiquitylation of RLRs via two distinct proteolytic pathways, effectively reducing canonical polyubiquitination and modulating antiviral immunity.
Integration with cellular stress responses
In simple terms: When cells are stressed, they adjust ubiquitination to survive or die.
HRD1-induced TMEM2 ubiquitination promotes ER stress-mediated apoptosis, while negative regulation of polyubiquitination can protect cells by stabilizing survival factors. This interplay is critical in ischemia/reperfusion injury.
Key Genes Involved in GO:1902915 negative regulation of protein polyubiquitination
The following genes and proteins are experimentally validated participants in negative regulation of protein polyubiquitination, as reported in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| OTUD7B | Deubiquitinase that removes ubiquitin from SQSTM1/p62 | Antiviral immunity, IRF3 degradation |
| OTUD5 | Deubiquitinase promoting α-synuclein degradation | Parkinson's disease neuroprotection |
| RNF167 | E3 ligase mediating atypical ubiquitylation of RLRs | Innate immune signaling |
| KLHL6 | Ubiquitin ligase driving resistance to CD8+ T cell dysfunction | Cancer immunotherapy |
| FBXO33 | E3 ligase regulating p53 polyubiquitination | Gallbladder cancer metastasis |
| HRD1 | E3 ligase inducing TMEM2 ubiquitination | ER stress and apoptosis |
| TRAF7 | E3 ligase controlling DBP degradation | Circadian rhythm |
| AMFR | E3 ligase stabilized by O-GlcNAcylation to regulate TSPAN4 | Viral release, migrasome formation |
| SQSTM1/p62 | Substrate of OTUD7B | Autophagy and antiviral signaling |
| α-Synuclein | Substrate of OTUD5 | Parkinson's disease |
| p53 | Substrate of FBXO33-mediated polyubiquitination | Cancer |
| TMEM2 | Substrate of HRD1 | ER stress |
| DBP | Substrate of TRAF7 | Circadian clock |
| TSPAN4 | Substrate of AMFR | Viral release |
| IRF3 | Downstream target of OTUD7B-SQSTM1 axis | Antiviral immunity |
| RLRs | Substrates of RNF167 | Innate immunity |
| CD8+ T cells | Affected by KLHL6 ubiquitination | T cell dysfunction |
| KLHL6 | Modulates T cell exhaustion | Cancer immunotherapy |
How Is negative regulation of protein polyubiquitination Regulated?
Negative regulation of protein polyubiquitination is itself regulated at multiple levels. Deubiquitinase activity can be controlled by post-translational modifications such as phosphorylation and O-GlcNAcylation, as seen with AMFR. E3 ligase stability and substrate accessibility are influenced by lactylation, as shown for FBXO33 in gallbladder cancer. Additionally, cellular stress pathways like ER stress can induce HRD1 to promote ubiquitination, indirectly affecting the balance of polyubiquitination. Circadian rhythms also modulate TRAF7-mediated DBP degradation.
negative regulation of protein polyubiquitination and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FBXO33 | Gallbladder cancer metastasis | KO and point mutation in gallbladder cancer cell lines |
| OTUD5 | Parkinson's disease | Knock-in and overexpression in dopaminergic neurons |
| OTUD7B | Antiviral immunity | KO in macrophages and dendritic cells |
| HRD1 | Intestinal ischemia/reperfusion | KO in intestinal epithelial cells |
| KLHL6 | Cancer immunotherapy | Overexpression and KO in CD8+ T cells |
Cancer
Dysregulation of negative regulation of polyubiquitination contributes to cancer. FBXO33-mediated p53 polyubiquitination promotes gallbladder cancer metastasis, and KLHL6 drives resistance to CD8+ T cell dysfunction in tumors. Targeting these pathways may enhance immunotherapy.
Neurodegeneration
OTUD5 protects dopaminergic neurons by promoting α-synuclein degradation, linking negative regulation of polyubiquitination to Parkinson's disease. Impaired DUB activity can lead to α-synuclein accumulation and neurotoxicity.
Antiviral immunity
OTUD7B deubiquitinates SQSTM1/p62 to promote IRF3 degradation, regulating antiviral immunity. RNF167 mediates atypical ubiquitylation of RLRs, fine-tuning innate immune responses.
ER stress and ischemia
HRD1-induced TMEM2 ubiquitination promotes ER stress-mediated apoptosis in intestinal ischemia/reperfusion, highlighting the role of ubiquitination balance in tissue injury.
From negative regulation of protein polyubiquitination-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of OTUD5 affect α-synuclein clearance? | OTUD5 knockout in dopaminergic neurons |
| Can point mutation in FBXO33 alter p53 polyubiquitination? | FBXO33 point-mutation knock-in in cancer cells |
| Does KLHL6 overexpression rescue T cell dysfunction? | KLHL6 overexpression in CD8+ T cells |
| How does O-GlcNAcylation of AMFR affect TSPAN4 stability? | AMFR knock-in with O-GlcNAc site mutation |
| Does HRD1 knockout protect against ER stress? | HRD1 knockout in intestinal epithelial cells |
| Can OTUD7B deubiquitinase activity be monitored in live cells? | Tagged knock-in of OTUD7B with fluorescent reporter |
How to Study the negative regulation of protein polyubiquitination Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ubiquitination assay | Polyubiquitin chain formation | Substrate validation |
| Mass spectrometry | Ubiquitination sites and chain topology | Global profiling |
| CRISPR screen | Gene essentiality for polyubiquitination | Novel regulator discovery |
| Live-cell imaging | Real-time ubiquitination dynamics | Subcellular localization |
| Co-immunoprecipitation | Protein-protein interactions | E3-substrate mapping |
| RNA-seq | Transcriptional changes | Pathway analysis |
| Ribo-seq | Translation efficiency | Stress response |
| Bioinformatics | Pathway enrichment and network analysis | Data integration |
Ubiquitination assays
In vitro and in vivo ubiquitination assays using tagged ubiquitin and immunoprecipitation can measure polyubiquitin chain formation on substrates like p53 or α-synuclein.
Proteomics and mass spectrometry
Mass spectrometry-based proteomics identifies ubiquitination sites and chain types, enabling global mapping of negative regulation events.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can uncover novel negative regulators of polyubiquitination in disease models.
Imaging and live-cell reporters
Fluorescently tagged ubiquitin or substrates allow real-time visualization of polyubiquitination dynamics and subcellular localization.
How CRISPR Can Be Used to Study GO:1902915 negative regulation of protein polyubiquitination
Knockout
CRISPR knockout of DUBs like OTUD5 or OTUD7B can reveal their role in stabilizing substrates and modulating disease phenotypes.
Point Mutation
Point mutations in catalytic residues of DUBs or E3 ligases can dissect enzymatic activity from scaffolding functions.
Knock-in
Knock-in of tagged ubiquitin or substrate variants allows tracking of polyubiquitination in live cells.
Overexpression
Overexpression of negative regulators like KLHL6 or OTUD5 can rescue disease phenotypes in cell models.
How EDITGENE Supports negative regulation of protein polyubiquitination Research
Researchers studying negative regulation of protein polyubiquitination-related genes often need to determine whether a candidate gene is causally involved in substrate stabilization, signaling, or disease progression. EDITGENE provides tailored CRISPR solutions to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of protein polyubiquitination research.
Frequently Asked Questions About negative regulation of protein polyubiquitination
What is GO:1902915?
GO:1902915 is a Gene Ontology biological process term for any process that stops, prevents or reduces the frequency, rate or extent of protein polyubiquitination.
What genes are involved in negative regulation of protein polyubiquitination?
Key genes include OTUD7B, OTUD5, RNF167, KLHL6, FBXO33, HRD1, TRAF7 and AMFR, which encode deubiquitinases or E3 ligases.
How does negative regulation of polyubiquitination affect cancer?
It can stabilize oncoproteins or tumor suppressors; for example, FBXO33-mediated p53 polyubiquitination promotes gallbladder cancer metastasis.
What diseases are linked to GO:1902915?
Cancer, Parkinson's disease, antiviral immunity defects, ER stress and circadian rhythm disorders have been associated with dysregulated polyubiquitination.
Which deubiquitinases negatively regulate polyubiquitination?
OTUD7B and OTUD5 are well-characterized deubiquitinases that remove ubiquitin chains from SQSTM1/p62 and α-synuclein, respectively.
How can I study negative regulation of protein polyubiquitination?
Use CRISPR knockout, point mutation, knock-in, overexpression models combined with ubiquitination assays, proteomics and imaging.
What is the role of OTUD5 in Parkinson's disease?
OTUD5 protects dopaminergic neurons by promoting α-synuclein degradation, reducing neurotoxicity.
Does O-GlcNAcylation regulate polyubiquitination?
Yes, O-GlcNAcylation of AMFR stabilizes TSPAN4 by limiting its polyubiquitination, affecting viral release.
What is the connection between KLHL6 and T cell dysfunction?
KLHL6 drives resistance to CD8+ T cell dysfunction, likely through ubiquitination of targets that modulate T cell exhaustion.
How does HRD1 influence ER stress?
HRD1-induced TMEM2 ubiquitination promotes ER stress-mediated apoptosis in intestinal ischemia/reperfusion.
Conclusion
GO:1902915, negative regulation of protein polyubiquitination, is a fundamental process that fine-tunes protein stability and signaling. Its dysregulation is implicated in cancer, neurodegeneration, immune disorders and stress responses. Understanding the enzymes and substrates involved offers therapeutic opportunities. EDITGENE's CRISPR services empower researchers to dissect these pathways with precision.
References
- 1. Cheng H et al.. 2026. The ubiquitin ligase KLHL6 drives resistance to CD8(+) T cell dysfunction.. Nature 651(8105):451-461 PMID: 41535474
- 2. He M et al.. 2025. RNF167 mediates atypical ubiquitylation and degradation of RLRs via two distinct proteolytic pathways.. Nat Commun 16(1):1920 PMID: 39994288
- 3. Xie W et al.. 2022. OTUD7B deubiquitinates SQSTM1/p62 and promotes IRF3 degradation to regulate antiviral immunity.. Autophagy 18(10):2288-2302 PMID: 35100065
- 4. Wu Z et al.. 2025. Lactylation-driven transcriptional activation of FBXO33 promotes gallbladder cancer metastasis by regulating p53 polyubiquitination.. Cell Death Dis 16(1):144 PMID: 40021626
- 5. Zhao X et al.. 2024. HRD1-induced TMEM2 ubiquitination promotes ER stress-mediated apoptosis through a non-canonical pathway in intestinal ischemia/reperfusion.. Cell Death Dis 15(2):154 PMID: 38378757
- 6. Song X et al.. 2025. OTUD5 Protects Dopaminergic Neurons by Promoting the Degradation of α-Synuclein in Parkinson's Disease Model.. Adv Sci (Weinh) 12(7):e2406700 PMID: 39721018
- 7. Masuda S et al.. 2024. TRAF7 determines circadian period through ubiquitination and degradation of DBP.. Commun Biol 7(1):1280 PMID: 39379486
- 8. Yu L et al.. 2026. O-GlcNAcylation of AMFR stabilizes TSPAN4 to regulate migrasome formation for viral release.. Nat Commun 17(1):1506 PMID: 41501039
